Multiple Speaking opportunities following the May JASN Publication on Phase2b trial kidney function data

FAST BioMedical Medical Advisory Board Member and Key Opinion Leader Dr. Andrew Shaw presented on mGFR at the 36th edition of the International Vicenza Course on Acute Kidney Injury and Continuous Renal Replacement Therapies on June 12^th. The event offered an updated course on the most important advances in the area of nephrology, critical care, cardiology and cardiac surgery. Dr. Shaw presented on mGFR and specifically on FAST’s recent Phase 2B clinical trial and JASN publication.

FAST BioMedical CEO Joe Muldoon presented in the Innovations spotlight at American Association on Kidney Patients (AAKP) Annual National Patient Meeting in June. He discussed and provided experienced insight into what mGFR and PV as innovations mean for renal patients. The AAKP Annual Meeting is the largest kidney patient education and advocacy meeting held in the United States.